ONC's Quality Score rose 1 point on Fri, Nov 6, to 22. Its 6-month gain reached 30%.
Follow ONC's trial news. Pro members can get an alert when BeOne Medicines files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 15% from Nov 3 to Nov 6 while the S&P 500 fell 3%.
“The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in the Company’s portfolio.”
| Sales | Up 56% a year for 3 years vs 5% for its peers |
| Latest filing | 8-K, Nov 5 |
Tue Nov 17: Jefferies 17th Annual London Global…Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed +0.2% on average, higher 3 of 4 times.
No shelf registration or at-the-market program on file in the last three years.
Director Xiaodong Wang sold 31,028 shares on Oct 27, under a planned sale. 45 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Exceptionalfor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. ONC scores 22 today, against a median of 15.5 over its last 20 recorded sessions.
ONC is #2 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score |
Net income over four quarters: ONC $916M, JAZZ $941M, RPRX $672M, TGTX $441M.
Expected to report Thu Feb 25, before the open (in 108 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $1.9B, 34% more than a year ago; a profit of $3.28 a share.
“The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in the Company’s portfolio.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Product | $1.9B | $1.7B | $1.4B |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)
| Measure | Figure |
|---|---|
| Total revenue | $6.9B to $7.0B |
“GAAP net income for the third quarter of 2026 was $385 million, an increase of $260 million over the prior-year period, primarily attributable to revenue growth and improved operating leverage.”
From its results filing (SEC filing · Nov 5)
Sales grew 77% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 6.3% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | +5.6% | +2.5% | not yet |
| Aug 5, 2026 | +1.9% | +1.4% | +11.2% |
| May 6, 2026 | +3.0% | +5.3% | +5.9% |
Sales grew in six of the last seven years, to $5.3B in 2025. It turned a profit in 2025 after a loss in 2024.
RSI 68.0, MACD above signal, above both averages. Not scored.
10 insiders sold $8M across 38 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
“We operate in a highly competitive global landscape, with our marketed products facing strong competition in regulated markets worldwide.”
ONC scores 22 today, which Breakaway calls Exceptional. It is #2 of 281 in Biotech by Quality Score, with 6 of 14 chart checks firing. Up 15% from Nov 3 to Nov 6 while the S&P 500 fell 3%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ONC scores 22 today, which Breakaway calls Exceptional (20 or more). That is #2 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ONC's 22.
10 insiders sold $8M across 38 filings in the last 6 months. No open-market buys on record. The newest is Titus B. Ball, Principal Accounting Officer, who sold $47K on Sep 1. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.